Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) CEO Oludare Odumosu tells Proactive the group has raised a total of $5 million from a US-based family office fund Quincy Street Capital to accelerate its growth initiatives.
Odumosu outlined how the group will use the funds, which include: Clinical development and ongoing trials in Australia and the US, additional licensing for Zelira Rx products and technologies, commercialisation of RAF FIVE™ products with a focus on rapid market penetration, and expansion of Zelira’s SprinjeneCBD footprint in the US and emerging global CBD markets.